Sunsure Life Science is an integrated life science group developing pharmaceuticals, consumer health products, and clinical AI — anchored in evidence, designed for access, and committed to the populations we serve. প্রমাণভিত্তিক বিজ্ঞান, যত্নশীল সেবা ও বুদ্ধিমান প্রযুক্তির সমন্বয়ে — বাংলাদেশ থেকে সারা বিশ্বে।
South Asian women of reproductive age affected by polycystic ovary syndrome.
Source: Endocrine Society, 2023Couples globally facing infertility — half attributable to a male factor.
Source: WHO, 2023Adult diabetes prevalence in Bangladesh — among the highest in South Asia.
Source: IDF Atlas, 11th ed.Specialist physician per 1,500 patients in many districts. AI-augmented care can extend reach.
Source: BMA / DGHS estimatesWe operate across the prescription, retail, and digital health channels — but every output is anchored in the same standard of evidence and the same therapeutic priorities.
Specialty pharmaceuticals for reproductive endocrinology and women's health, distributed through an established network of prescribers and diagnostic centers under DGDA-licensed operations.
View portfolio →A clinically-formulated women's wellness brand built around the Myo-Inositol & D-Chiro Inositol 40:1 ratio supported by reproductive endocrinology literature, with international quality controls and direct-to-consumer distribution.
Visit brand →A clinical-decision-support platform unifying personal health records, AI-assisted differential diagnosis, and diagnostic workflow integration — referenced against international guidelines (WHO, NEJM, Harrison's).
Open platform →Every formulation we develop and every recommendation we surface is reviewed against the strongest available evidence. We choose actives, ratios, and dosages with reference to peer-reviewed literature and international clinical guidelines.
Our flagship women's health work is built around insulin-sensitizing inositol stereoisomers in the physiologic 40:1 ratio — an approach with consistent support across randomized trials in PCOS-related ovulatory dysfunction and metabolic outcomes.
REF · Unfer et al., Eur Rev Med Pharmacol Sci (2017) · Nordio & Proietti (2012)Half of all infertility cases involve a male factor, yet the category is under-served clinically and commercially. Our male fertility work draws on antioxidant and micronutrient evidence (CoQ10, L-carnitine, zinc, selenium, folate) shown to influence sperm parameters in meta-analyses.
REF · Cochrane Database Syst Rev · Salas-Huetos et al. (2017)MediAI's role is to extend the physician — surfacing differential diagnoses, flagging interactions, and translating reports — while preserving the clinician's authority over the final decision. All outputs cite the source.
REF · WHO Ethics & Governance of AI for Health (2021)A medicine that cannot reach the patient is a medicine that does not exist. We build distribution, pricing, and digital infrastructure with the same seriousness we apply to formulation — because access is the final mile of efficacy.
REF · Lancet Commission on Essential Medicines Policies (2017)The strength of a health system is measured not by what it can prescribe, but by who it can reach.
Our quality framework does not change between markets. The same standards governing an OVAVITA bottle on a U.S. shelf govern a Sunsure prescription in a Dhaka clinic.
All consumer health and supplement products are manufactured by partners holding current Good Manufacturing Practice certification under WHO and ICH-Q7 frameworks.
Sunsure Pharma operates under Directorate General of Drug Administration oversight in Bangladesh, with full compliance to local pharmacovigilance and labeling standards.
Products entering the United States are positioned under the Dietary Supplement Health and Education Act, with appropriate New Dietary Ingredient notification where applicable.
Recommendations issued through MediAI cite peer-reviewed literature, WHO guidelines, or BMDC-aligned standards — and surface those references to the clinician.
We maintain a structured adverse-event reporting framework across all divisions, with a published contact pathway for clinicians and patients.
Beyond our commercial divisions, Sunsure is establishing a foundation focused on diagnostic awareness and treatment access for rare and metabolic neurological conditions in Bangladesh — beginning with disorders such as Wilson's disease, where early identification and timely chelation therapy alter the trajectory of life.
The foundation will support clinician education, screening initiatives in tertiary hospitals, and partnerships with international compassionate-use programs that bring therapy to families who would otherwise face it alone.
সচেতনতা, প্রাথমিক রোগনির্ণয় ও আন্তর্জাতিক সহানুভূতিশীল চিকিৎসা সহায়তায় — আমাদের দীর্ঘমেয়াদী অঙ্গীকার।
Whether you practise medicine, run a diagnostic service, or distribute health products — we'd like to begin a conversation.
Access product monographs, request clinical samples for the Fort Series, and join a network of prescribers committed to evidence-led women's health.
Request access →Integrate MediAI's clinical reporting and decision-support layer to deliver more interpretive value with your imaging and laboratory results.
Explore B2B →Partner across Bangladesh, the GCC, and selected international markets for Sunsure Pharma and OVAVITA™ portfolios under structured commercial terms.
Begin discussion →For partnership, distribution, clinical, regulatory, or media inquiries, our team responds within two business days.
HeadquartersSunsure Life Science Ltd.
Dhaka, Bangladesh
Sunsure Life Science LLC
State of Wyoming, United States